3 Mar 2026 New GLP-1 Pill Outperforms Oral Semaglutide in Blood Glucose Levels A new non-peptide GLP-1 pill proved more effective for weight loss than oral semaglutide in a recent Phase III trial
Sophie Dix (BSc, PhD) Published: 9 February 2026 | Updated: 18 June 2026 Updated: 18 June 2026 Reading time: 10 minutes Quick navigation: Article Summary Mounjaros "golden dose," and the "fifth pen" phenomenon The prescribed Mounjaro dosing schedule and titration The purpose of titration: Gradually adapting to the medication Finding your ideal dose The origins of the "golden dose" concept The "liquid left" phenomenon: Why there's residual medication in the pen The real risks of misusing the "5th pen" or deviating from prescribed dosing Risk of infection and device malfunction Losing clinical oversight: The dangers of self-medication Personalised dosing: Finding your true optimal Mounjaro dose Key factors influencing your personalised dose The indispensable role of your clinician Effective communication with your prescriber Navigating your Mounjaro journey for sustainable success The real "golden dose" is personalised, clinically guided care Ready to start your weight loss journey
Semaglutide is administered subcutaneously (under the skin) and works through hormonal pathways, while collagen is a dietary protein processed by your digestive system
Delivery method: Injectable (subcutaneous), oral capsules, or oral spray
Table 1 summarizes MSTN signaling inhibitors currently being tested for metabolic disorders, and these clinical trials highlight the emerging role of MSTN inhibitors as potent agents to counteract the loss of lean mass commonly observed with GLP-1 agonist therapy
